Top

Published in:

Open Access 01-12-2022 | Pneumococcus | Research

In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant

Authors: Zohreh Bahadori, Mona Shafaghi, Hamid Madanchi, Mohammad Mehdi Ranjbar, Ali Akbar Shabani, Seyed Fazlollah Mousavi

Published in: Journal of Translational Medicine | Issue 1/2022

Abstract

Background

Streptococcus pneumoniae is the leading reason for invasive diseases including pneumonia and meningitis, and also secondary infections following viral respiratory diseases such as flu and COVID-19. Currently, serotype-dependent vaccines, which have several insufficiency and limitations, are the only way to prevent pneumococcal infections. Hence, it is plain to need an alternative effective strategy for prevention of this organism. Protein-based vaccine involving conserved pneumococcal protein antigens with different roles in virulence could provide an eligible alternative to existing vaccines.

Methods

In this study, PspC, PhtD and PsaA antigens from pneumococcus were taken to account to predict B-cell and helper T-cell epitopes, and epitope-rich regions were chosen to build the construct. To enhance the immunogenicity of the epitope-based vaccine, a truncated N-terminal fragment of pneumococcal endopeptidase O (PepO) was used as a potential TLR2/4 agonist which was identified by molecular docking studies. The ultimate construct was consisted of the chosen epitope-rich regions, along with the adjuvant role (truncated N-PepO) and suitable linkers.

Results

The epitope-based vaccine was assessed as regards physicochemical properties, allergenicity, antigenicity, and toxicity. The 3D structure of the engineered construct was modeled, refined, and validated. Molecular docking and simulation of molecular dynamics (MD) indicated the proper and stable interactions between the vaccine and TLR2/4 throughout the simulation periods.

Conclusions

For the first time this work presents a novel vaccine consisting of epitopes of PspC, PhtD, and PsaA antigens which is adjuvanted with a new truncated domain of PepO. The computational outcomes revealed that the suggested vaccine could be deemed an efficient therapeutic vaccine for S. pneumoniae; nevertheless, in vitro and in vivo examinations should be performed to prove the potency of the candidate vaccine.

Available only for authorised users

Weiser JN, Ferreira DM, Paton JC. Streptococcus pneumoniae: transmission, colonization and invasion. Nat Rev Microbiol. 2018;16(6):355. https://doi.org/10.1038/s41579-018-0001.CrossRefPubMedPubMedCentral

Liu X, Kimmey JM, Matarazzo L, de Bakker V, Van Maele L, Sirard J-C, et al. Exploration of bacterial bottlenecks and Streptococcus pneumoniae pathogenesis by CRISPRi-Seq. Cell Host Microbe. 2021;29(1):107–20. https://doi.org/10.1016/j.chom.2020.10.001.CrossRefPubMed

Brueggemann AB, van Rensburg MJJ, Shaw D, McCarthy ND, Jolley KA, Maiden MC, et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digital Health. 2021;3(6):e360–70. https://doi.org/10.1016/S2589-7500(21)00077-7.CrossRefPubMed

Organization WH. Pneumococcal conjugate vaccine for childhood immunization—WHO position paper. The weekly epidemiological record. 2007;82(12):93–104.https://apps.who.int/iris/handle/10665/240895.

Malley RJJomm. Antibody and cell-mediated immunity to Streptococcus pneumoniae: implications for vaccine development. J Molecular Med. 2010;88:135–42. https://doi.org/10.1007/s00109-009-0579-4.CrossRef

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. https://doi.org/10.1086/648593.CrossRefPubMed

Lagousi T, Basdeki P, Routsias J, Spoulou V. Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens. Vaccines. 2019;7(1):9. https://doi.org/10.3390/vaccines7010009.CrossRefPubMedCentral

Alderson MRJV. Status of research and development of pediatric vaccines for Streptococcus pneumoniae. Vaccine. 2016;34(26):2959–61. https://doi.org/10.1016/j.vaccine.2016.03.107.CrossRefPubMedPubMedCentral

Berry AM, Paton JCJI. Immunity Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun. 2000;68(1):133–40. https://doi.org/10.1128/IAI.68.1.133-140.2000.CrossRefPubMedPubMedCentral

10.

Kerr AR, Paterson GK, McCluskey J, Iannelli F, Oggioni MR, Pozzi G, et al. The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms. Infect Immun. 2006;74(9):5319–24. https://doi.org/10.1128/IAI.00543-06.CrossRefPubMedPubMedCentral

11.

Guerra AJ, Dann III CE, Giedroc DPJJotACS. Crystal structure of the zinc-dependent MarR family transcriptional regulator AdcR in the Zn (II)-bound state. J Am Chem Soc. 2011;133(49):19614–7. https://doi.org/10.1021/ja2080532.CrossRefPubMedPubMedCentral

12.

Plumptre CD, Ogunniyi AD, Paton JC. Vaccination against Streptococcus pneumoniae using truncated derivatives of polyhistidine triad protein D. PLoS ONE. 2013;8(10):e78916. https://doi.org/10.1371/journal.pone.0078916.CrossRefPubMedPubMedCentral

13.

Cundell D, Pearce B, Sandros J, Naughton A, Masure HJI. Immunity peptide permeases from Streptococcus pneumoniae affect adherence to eucaryotic cells. Infect Immun. 1995;63(7):2493–8. https://doi.org/10.1128/iai.63.7.2493-2498.1995.CrossRefPubMedPubMedCentral

14.

Jomaa M, Yuste J, Paton JC, Jones C, Dougan G, Brown JSJI, et al. Antibodies to the iron uptake ABC transporter lipoproteins PiaA and PiuA promote opsonophagocytosis of Streptococcus pneumoniae. Infect Immun. 2005;73(10):6852–9. https://doi.org/10.1128/IAI.73.10.6852-6859.2005.CrossRefPubMedPubMedCentral

15.

Daniels CC, Coan P, King J, Hale J, Benton KA, Briles DE, et al. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun. 2010;78(5):2163–72. https://doi.org/10.1128/IAI.01199-09.CrossRefPubMedPubMedCentral

16.

Masomian M, Ahmad Z, Ti Gew L, Poh CLJV. Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines. 2020;8(1):132. https://doi.org/10.3390/vaccines8010132.CrossRefPubMedCentral

17.

Janulczyk R, Iannelli F, Sjöholm AG, Pozzi G, Björck LJJoBC. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem. 2000;275(47):37257–63. https://doi.org/10.1074/jbc.M004572200.CrossRefPubMed

18.

Cheng Q, Finkel D, Hostetter MKJB. Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry. 2000;39(18):5450–7. https://doi.org/10.1021/bi992157d.CrossRefPubMed

19.

Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GSJMm. SpsA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin a and secretory component. Molecul Microbiol. 1997;25(6):1113–24. https://doi.org/10.1046/j.1365-2958.1997.5391899.x.CrossRef

20.

Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol. 1997;25(5):819–29. https://doi.org/10.1111/j.1365-2958.1997.mmi494.x.CrossRefPubMed

21.

Brooks-Walter A, Briles DE, Hollingshead SKJI. Immunity the pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infection Immunity. 1999;67(12):6533–42. https://doi.org/10.1128/IAI.67.12.6533-6542.1999.CrossRefPubMedPubMedCentral

22.

Iannelli F, Oggioni MR, Pozzi GJG. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae. Gene. 2002;284(1–2):63–71. https://doi.org/10.1016/S0378-1119(01)00896-4.CrossRefPubMed

23.

Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DEJI. Immunity role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infection Immunity. 2002;70(5):2526–34. https://doi.org/10.1128/IAI.70.5.2526-2534.2002.CrossRefPubMedPubMedCentral

24.

Moreno AT, Oliveira MLS, Ho PL, Vadesilho CF, Palma GM, Ferreira JM Jr, et al. Cross-reactivity of antipneumococcal surface protein C (PspC) antibodies with different strains and evaluation of inhibition of human complement factor H and secretory IgA binding via PspC. Clin Vaccine Immunol. 2012;19(4):499–507. https://doi.org/10.1128/CVI.05706-11.CrossRefPubMedPubMedCentral

25.

Malekan M, Siadat SD, Aghasadeghi M, Shahrokhi N, Afrough P, Behrouzi A, et al. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants. J Med Microbiol. 2020;69(3):465–77. https://doi.org/10.1099/jmm.0.001103.CrossRefPubMed

26.

Bersch B, Bougault C, Roux L, Favier A, Vernet T, Durmort C. New insights into histidine triad proteins: solution structure of a Streptococcus pneumoniae PhtD domain and zinc transfer to AdcAII. PLoS ONE. 2013;8(11):e81168. https://doi.org/10.1371/journal.pone.0081168.CrossRefPubMedPubMedCentral

27.

Ogunniyi AD, Grabowicz M, Mahdi LK, Cook J, Gordon DL, Sadlon TA, et al. Pneumococcal histidine triad proteins are regulated by the Zn2+-dependent repressor AdcR and inhibit complement deposition through the recruitment of complement factor H. FASEB J. 2009;23(3):731–8. https://doi.org/10.1096/fj.08-119537.CrossRefPubMed

28.

Rioux S, Neyt C, Di Paolo E, Turpin L, Charland N, Labbe S, et al. Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae. Microbiology. 2011;157(2):336–48. https://doi.org/10.1099/mic.0.042184-0.CrossRefPubMed

29.

Kallio A, Sepponen K, Hermand P, Denoël P, Godfroid F, Melin M. Role of Pht proteins in attachment of Streptococcus pneumoniae to respiratory epithelial cells. Infect Immun. 2014;82(4):1683–91. https://doi.org/10.1128/IAI.00699-13.CrossRefPubMedPubMedCentral

30.

Beghetto E, Gargano N, Ricci S, Garufi G, Peppoloni S, Montagnani F, et al. Discovery of novel Streptococcus pneumoniae antigens by screening a whole-genome λ-display library. FEMS Microbiol Lett. 2006;262(1):14–21. https://doi.org/10.1111/j.1574-6968.2006.00360.x.CrossRefPubMed

31.

Yu J, Li B, Chen X, Lu J, Wang D, Gu T, et al. Comparison of immunogenicity and protection of two pneumococcal protein vaccines based on PsaA and PspA. Infect Immun. 2018;86(6):e00916-e917. https://doi.org/10.1128/IAI.00916-17.CrossRefPubMedPubMedCentral

32.

Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, et al. Protective immune responses elicited by fusion protein containing PsaA and PspA fragments. Immunol Invest. 2015;44(5):482–96. https://doi.org/10.3109/08820139.2015.1037956.CrossRefPubMed

33.

Sampson JS, Furlow Z, Whitney AM, Williams D, Facklam R, Carlone GMJI, et al. Limited diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes. Infect Immun. 1997;65(5):1967–71. https://doi.org/10.1128/iai.65.5.1967-1971.1997.CrossRefPubMedPubMedCentral

34.

Rajam G, Anderton JM, Carlone GM, Sampson JS, Ades EW. Pneumococcal surface adhesin a (PsaA): a review. Crit Rev Microbiol. 2008;34(3–4):131–42. https://doi.org/10.1080/10408410802275352.CrossRefPubMed

35.

Wang S, Li Y, Shi H, Scarpellini G, Torres-Escobar A, Roland KL, et al. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun. 2010;78(7):3258–71. https://doi.org/10.1128/IAI.00176-10.CrossRefPubMedPubMedCentral

36.

McDevitt CA, Ogunniyi AD, Valkov E, Lawrence MC, Kobe B, McEwan AG, et al. A molecular mechanism for bacterial susceptibility to zinc. PLoS Pathog. 2011;7(11):e1002357. https://doi.org/10.1371/journal.ppat./1002357.CrossRefPubMedPubMedCentral

37.

Dorosti H, Eslami M, Negahdaripour M, Ghoshoon MB, Gholami A, Heidari R, et al. Vaccinomics approach for developing multi-epitope peptide pneumococcal vaccine. J Biomol Struct Dyn. 2019;37(13):3524–35. https://doi.org/10.1080/07391102.2018.1519460.CrossRefPubMed

38.

Tartey S, Takeuchi OJIRoI. Pathogen recognition and toll-like receptor targeted therapeutics in innate immune cells. Internat Rev Immunol. 2017;36(2):57–73. https://doi.org/10.1080/08830185.2016.1261318.CrossRef

39.

Kumar S, Sunagar R, Gosselin EJFii. Bacterial protein toll-like-receptor agonists: a novel perspective on vaccine adjuvants. Front Immunol. 2019;10:1144. https://doi.org/10.3389/fimmu.2019.01144.CrossRefPubMedPubMedCentral

40.

Zhang H, Kang L, Yao H, He Y, Wang X, Xu W, et al. Streptococcus pneumoniae endopeptidase O (PepO) elicits a strong innate immune response in mice via TLR2 and TLR4 signaling pathways. Front Cell Infect Microbiol. 2016;6:23. https://doi.org/10.3389/fcimb.2016.00023.CrossRefPubMedPubMedCentral

41.

Shu Z, Yuan J, Wang H, Zhang J, Li S, Zhang H, et al. Streptococcus pneumoniae PepO promotes host anti-infection defense via autophagy in a Toll-like receptor 2/4 dependent manner. Virulence. 2020;11(1):270–82. https://doi.org/10.1080/21505594.2020.1739411.CrossRefPubMedPubMedCentral

42.

Khan M, Khan S, Ali A, Akbar H, Sayaf AM, Khan A, et al. Immunoinformatics approaches to explore helicobacter pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. Sci Rep. 2019;9(1):1–13. https://doi.org/10.1038/s41598-019-49354-z.CrossRef

43.

Tahirul QM, Bari A, Adeel MM, Maryam A, Ashfaq UA, Du X, et al. Peptide vaccine against chikungunya virus: immuno-informatics combined with molecular docking approach. Transl Med. 2018;16(1):1–14. https://doi.org/10.1186/s12967-018-1672-7.CrossRef

44.

Fereshteh S, Abdoli S, Shahcheraghi F, Ajdary S, Nazari M, Badmasti FJMp. New putative vaccine candidates against Acinetobacter baumannii using the reverse vaccinology method. Micro Pathogen. 2020;143:104114. https://doi.org/10.1016/j.micpath.2020.104114.CrossRef

45.

Krogh A, Larsson B, Von Heijne G, Sonnhammer ELJJomb. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Molecular Biol. 2001;305(3):567–80. https://doi.org/10.1006/jmbi.2000.4315.CrossRef

46.

Armenteros JJA, Salvatore M, Emanuelsson O, Winther O, Von Heijne G, Elofsson A, et al. Detecting sequence signals in targeting peptides using deep learning. Life Sci Allian. 2019;2(5):1–14. https://doi.org/10.26508/lsa.201900429.CrossRef

47.

Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang YJNm. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12(1):7–8. https://doi.org/10.1038/nmeth.3213.CrossRefPubMedPubMedCentral

48.

Zhang YJBb. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9(1):1–8. https://doi.org/10.1186/1471-/2105-9-40.CrossRef

49.

Kabsch WJACSACP. Diffraction, theoretical, crystallography g a discussion of the solution for the best rotation to relate two sets of vectors. Acta Cryst Section A. 1978;34(5):827–8. https://doi.org/10.1107/S0567739478001680.CrossRef

50.

Shin W-H, Lee GR, Heo L, Lee H, Seok CJBD. Prediction of protein structure and interaction by GALAXY protein modeling programs. Bio Design. 2014;2(1):1–11.

51.

Wiederstein M, Sippl MJJNar. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(2):W407–10. https://doi.org/10.1093/nar/gkm290.CrossRefPubMedPubMedCentral

52.

Laskowski RA, MacArthur MW, Moss DS, Thornton JMJJoac. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystall. 1993;26(2):283–91. https://doi.org/10.1107/S0021889892009944.CrossRef

53.

Saha S, Raghava GPSJPS. Function prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins: Struct Funct Bioinformat. 2006;65(1):40–8. https://doi.org/10.1002/prot.21078.CrossRef

54.

Singh H, Ansari HR, Raghava GP. Improved method for linear B-cell epitope prediction using antigen’s primary sequence. PLoS ONE. 2013;8(5):e62216. https://doi.org/10.1371/journal.pone.0062216.CrossRefPubMedPubMedCentral

55.

Emini EA, Hughes JV, Perlow D, Boger J. Induction of hepatitis a virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985;55(3):836–9. https://doi.org/10.1128/jvi.55.3.836-839.1985.CrossRefPubMedPubMedCentral

56.

Ponomarenko J, Bui H-H, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9(1):1–8. https://doi.org/10.1186/1471-2105-9-514.CrossRef

57.

Kringelum JV, Lundegaard C, Lund O, Nielsen MJPcb. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829. https://doi.org/10.1371/journal.pcbi.1002829.CrossRefPubMedPubMedCentral

58.

Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters BJPcb. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Computational Biol. 2008;4(4):e1000048. https://doi.org/10.1371/journal.pcbi./1000048.CrossRef

59.

Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394–406. https://doi.org/10.1111/imm.12889.CrossRefPubMedPubMedCentral

60.

van de Garde MDB, van Westen E, Poelen MCM, Rots NY, van Els CACM. Prediction and validation of immunogenic domains of pneumococcal proteins recognized by human CD4+ T cells. Infect Immun. 2019;87(6):e00098–19. https://doi.org/10.1128/IAI.00098-19.CrossRefPubMedPubMedCentral

61.

Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The cluspro web server for protein–protein docking. Nat Protoc. 2017;12(2):255–78. https://doi.org/10.1038/nprot.2016.169.CrossRefPubMedPubMedCentral

62.

Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng Des Sel. 1995;8(2):127–34. https://doi.org/10.1093/protein/8.2,127.CrossRef

63.

Tian H, Hou X, Liu X. Real-time SPR characterization of the interactions between multi-epitope proteins and antibodies against classical swine fever virus. Biochem Biophys Res Commun. 2013;431(2):315–20. https://doi.org/10.1016/j.bbrc.2012.12.104.CrossRefPubMed

64.

Ahmad S, Shahid F, Tahirul QM, Abbasi SW, Sajjad W, Ismail S, et al. Immuno-informatics analysis of pakistan-based HCV subtype-3a for chimeric polypeptide vaccine design. Vaccines. 2021;9(3):293. https://doi.org/10.3390/vaccines9030293.CrossRefPubMedPubMedCentral

65.

Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T. Design of the linkers which effectively separate domains of a bifunctional fusion protein. Protein Eng Des Sel. 2001;14(8):529–32. https://doi.org/10.1093/protein/14.8,529.CrossRef

66.

Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinf. 2007;8(1):1–7. https://doi.org/10.1186/1471-2105-8-4.CrossRef

67.

Magnan CN, Zeller M, Kayala MA, Vigil A, Randall A, Felgner PL, et al. High-throughput prediction of protein antigenicity using protein microarray data. Bioinformatics. 2010;26(23):2936–43. https://doi.org/10.1093/bioinformatics/btq551.CrossRefPubMedPubMedCentral

68.

Saha S, Raghava GPSJNar. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(2):W202–9. https://doi.org/10.1093/nar/gkl343.CrossRefPubMedPubMedCentral

69.

Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v 2—a server for in silico prediction of allergens. J Molecular Model. 2014;20(6):1–6. https://doi.org/10.1007/s00894-014-2278-5.CrossRef

70.

Magnan CN, Randall A, Baldi PJB. SOLpro: accurate sequence-based prediction of protein solubility. Bioinformatics. 2009;25(17):2200–7. https://doi.org/10.1093/bioinformatics/btp386.CrossRefPubMed

71.

Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R. In silico approach for predicting toxicity of peptides and proteins. PLoS ONE. 2013;8:e73957. https://doi.org/10.1371/journal.pone/0073957.CrossRefPubMedPubMedCentral

72.

Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch AJTpph. Protein identification and analysis tools on the ExPASy server. Proteomics Proto Handbook. 2005. https://doi.org/10.1385/1-59259-890-0/571.CrossRef

73.

Kim DE, Chivian D, Baker DJNar. Protein structure prediction and analysis using the robetta server. Nucl Acids Res. 2004;32(2):W526–31. https://doi.org/10.1093/nar/gkh468.CrossRefPubMedPubMedCentral

74.

Colovos C, Yeates TOJPs. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2(9):1511–9. https://doi.org/10.1002/pro.5560020916.CrossRefPubMedPubMedCentral

75.

Hess B, Kutzner C, Van Der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435–47. https://doi.org/10.1021/ct700301q.CrossRefPubMed

76.

Schmid N, Eichenberger AP, Choutko A, Riniker S, Winger M, Mark AE, et al. Definition and testing of the GROMOS force-field versions 54A7 and 54B7. Eur Biophys J. 2011;40(7):843–56. https://doi.org/10.1007/s00249-011-0700-9.CrossRefPubMed

77.

Bahadori Z, Shabani AA, Minuchehr Z. Rational design of hyper-glycosylated human follicle-stimulating hormone analogs (a bioinformatics approach). J Biomol Struct Dyn. 2021;40(16):1–12. https://doi.org/10.1080/07391102.2021.1924268.CrossRef

78.

Nabizadeh Z, Minuchehr Z, Shabani AA. Rational design of hyper-glycosylated human chorionic gonadotropin analogs (a bioinformatics approach). Lett Drug Des Discovery. 2020;17(8):1001–14. https://doi.org/10.2174/1570180817666200225101938.CrossRef

79.

Rapin N, Lund O, Bernaschi M, Castiglione FJPo. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. PLoS ONE. 2010;5(4):e9862. https://doi.org/10.1371/journal.pone.0009862.CrossRefPubMedPubMedCentral

80.

Castiglione F, Mantile F, De Berardinis P, Prisco AJC, medicine mmi. How the interval between prime and boost injection affects the immune response in a computational model of the immune system. 2012;2012.

81.

Grote A, Hiller K, Scheer M, Münch R, Nörtemann B, Hempel DC, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucl Acids Res. 2005;33(2):W526–31. https://doi.org/10.1093/nar.gki376.CrossRefPubMedPubMedCentral

82.

Loughran AJ, Orihuela CJ, Tuomanen EI. Streptococcus pneumoniae: Invasion and inflammation. Microbiol Spect. 2019;7(2):1–31. https://doi.org/10.1128/microbiolspec.GPP3-0004-2018.CrossRef

83.

Petukhova E, Vorobyev D, Sidorov A, Semenova I, Volokh Y, Leonova A, et al. Immunization with recombinant pneumolysin induces the production of antibodies and protects mice in a model of systemic infection caused by Streptococcus pneumoniae. Bull Exp Biol Med. 2020;168(4):485–7. https://doi.org/10.1007/s10517-020-04736-6.CrossRefPubMed

84.

Yu J, Chen X, Li B, Gu T, Meng X, Kong W, et al. A pneumococcal vaccine combination with two proteins containing PspA families 1 and 2 can potentially protect against a wide range of Streptococcus pneumoniae strains. Immunol Res. 2018;66(4):528–36. https://doi.org/10.1007/s12026-018-9016-5.CrossRefPubMed

85.

Shafaghi M, Shabani AA, Minuchehr Z. Rational design of hyper-glycosylated human luteinizing hormone analogs (a bioinformatics approach). Comput Biol Chem. 2019;79:16–23. https://doi.org/10.1016/j.compbiolchem.2019.01.002.CrossRefPubMed

86.

Gautam A, Chaudhary K, Kumar R, Sharma A, Kapoor P, Tyagi A, et al. In silico approaches for designing highly effective cell penetrating peptides. Transl Med. 2013;11(1):1–12. https://doi.org/10.1186/1479-5876-11-74.CrossRef

87.

Tomar N, De RK. Immunoinformatics: an integrated scenario. Immunology. 2010;131(2):153–68. https://doi.org/10.1111/j.1365-2567.2010/03330.x.CrossRefPubMedPubMedCentral

88.

Idrees S, Ashfaq UA, Khaliq SJJotm. HCV Envelope protein 2 sequence comparison of Pakistani isolate and In-silico prediction of conserved epitopes for vaccine development. Transl Med. 2013;11(1):1–9. https://doi.org/10.1186/1479-5876-11-105.CrossRef

89.

Huang P, Yu S, Wu C, Liang LJJotm. Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. Transl Med. 2013;11(1):1–8. https://doi.org/10.1186/1479-5876-11-47.CrossRef

90.

Tischer S, Geyeregger R, Kwoczek J, Heim A, Figueiredo C, Blasczyk R, et al. Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection. Transl Med. 2016;14(1):1–16. https://doi.org/10.1186/s12967-016-1042-2.CrossRef

91.

Tahir ul QM, Saleem S, Ashfaq UA, Bari A, Anwar F, Alqahtani SJJotm. Epitope-based peptide vaccine design and target site depiction against middle east respiratory syndrome coronavirus: an immune-informatics study. Transl Med. 2019;17(1):1–14. https://doi.org/10.1186/s12967-019-2116-8.CrossRef

92.

Banerjee A, Santra D, Maiti SJJoTM. Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development. Transl Med. 2020;18(1):1–14. https://doi.org/10.1186/s12967-020/02435-4.CrossRef

93.

Raoufi E, Hemmati M, Eftekhari S, Khaksaran K, Mahmodi Z, Farajollahi MM, et al. Epitope prediction by novel immunoinformatics approach: a state-of-the-art review. Int J Pept Res Ther. 2020;26(2):1155–63. https://doi.org/10.1007/s10989-019-09918-z.CrossRefPubMed

94.

Ogunniyi AD, Woodrow MC, Poolman JT, Paton JC. Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA. Infect Immun. 2001;69(10):5997–6003. https://doi.org/10.1128/IAI.69.10.5997-6003.2001.CrossRefPubMedPubMedCentral

95.

Mann B, Thornton J, Heath R, Wade KR, Tweten RK, Gao G, et al. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid–CbpA peptide recombinant fusion protein. J Infect Dis. 2014;209(7):1116–25. https://doi.org/10.1093/infdis/jit502.CrossRefPubMed

96.

Godfroid F, Hermand P, Verlant V, Denoël P, Poolman JT. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun. 2011;79(1):238–45. https://doi.org/10.1128/IAI.00378-10.CrossRefPubMed

97.

Khan MN, Pichichero ME. Vaccine candidates PhtD and PhtE of Streptococcus pneumoniae are adhesins that elicit functional antibodies in humans. Vaccine. 2012;30(18):2900–7. https://doi.org/10.1016/j.vaccine.2012.02.023.CrossRefPubMedPubMedCentral

98.

Verhoeven D, Xu Q, Pichichero MEJV. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model. Vaccine. 2014;32(26):3205–10. https://doi.org/10.1016/j.vaccine.2014.04.004.CrossRefPubMed

99.

De B, Sampson J, Ades E, Huebner R, Jue D, Johnson S, et al. Purification and characterization of Streptococcus pneumoniae palmitoylated pneumococcal surface adhesin a expressed in Escherichia coli. Vaccine. 2000;18(17):1811–21. https://doi.org/10.1016/S0264-410X(99)00481-8.CrossRefPubMed

100.

Lin H, Lin Z, Meng C, Huang J, Guo Y. Preparation and immunogenicity of capsular polysaccharide–surface adhesin a (PsaA) conjugate of Streptococcus pneumoniae. Immunobiology. 2010;215(7):545–50. https://doi.org/10.1016/j.imbio.2009.08.008.CrossRefPubMed

101.

Lu Y-J, Forte S, Thompson CM, Anderson PW, Malley R. Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun. 2009;77(5):2076–83. https://doi.org/10.1128/IAI.01554-08.CrossRefPubMedPubMedCentral

102.

Briles DE, Ades E, Paton JC, Sampson JS, Carlone GM, Huebner RC, et al. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun. 2000;68(2):796–800. https://doi.org/10.1128/IAI.68.2.796-800.2000.CrossRefPubMedPubMedCentral

103.

Rueckert C, Guzmán CA. Vaccines: from empirical development to rational design. PLoS Pathog. 2012;8(11):e1003001. https://doi.org/10.1371/journal.ppat.1003001.CrossRefPubMedPubMedCentral

104.

Sanami S, Azadegan-Dehkordi F, Rafieian-Kopaei M, Salehi M, Ghasemi-Dehnoo M, Mahooti M, et al. Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approaches. Scientific Rep. 2021;11(1):1–15. https://doi.org/10.1038/s41598-021-91997-4.CrossRef

105.

Sayed SB, Nain Z, Khan MSA, Abdulla F, Tasmin R, Adhikari, UKJIjopr, et al. Exploring lassa virus proteome to design a multi-epitope vaccine through immunoinformatics and immune simulation analyses. Int J Pept Res Therap. 2020;26(4):2089–107. https://doi.org/10.1007/s10989-019-10003-8.CrossRef

106.

Bukhari SNH, Jain A, Haq E, Mehbodniya A, Webber JJP. Machine learning techniques for the prediction of B-Cell and T-Cell epitopes as potential vaccine targets with a specific focus on SARS-CoV-2 pathogen: a review. Pathogens. 2022;11(2):146. https://doi.org/10.3390/pathogens11020146.CrossRefPubMedPubMedCentral

107.

Khan MT, Islam MJ, Parihar A, Islam R, Jerin TJ, Dhote R, et al. Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2. Inf Med. 2021;24:100578. https://doi.org/10.1016/j.imu.2021.100578.CrossRef

108.

Rai J, Lok KI, Mok CY, Mann H, Noor M, Patel P, et al. Immunoinformatic evaluation of multiple epitope ensembles as vaccine candidates: E coli 536. Bioinformation. 2012;8(6):272. https://doi.org/10.6026/97320630008272.CrossRefPubMedPubMedCentral

109.

Negahdaripour M, Nezafat N, Eslami M, Ghoshoon MB, Shoolian E, Najafipour S, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. Infect Genet Evol. 2018;58:96–109. https://doi.org/10.1016/j.meegid.2017.12.008.CrossRefPubMed

110.

Khatoon N, Pandey RK, Prajapati VKJSr. Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Sci Rep. 2017;7(1):1–12. https://doi.org/10.1038/s41598-017-08842-w.CrossRef

111.

Shey RA, Ghogomu SM, Esoh KK, Nebangwa ND, Shintouo CM, Nongley NF, et al. In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases. Sci Rep. 2019;9(1):1–18. https://doi.org/10.1038/s41598-019-40833-x.CrossRef

112.

Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, et al. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in vibrio cholerae targeted by piper betel derived compounds. PLoS ONE. 2013;8(1):e52773. https://doi.org/10.1371/journal.pone.0052773.CrossRefPubMedPubMedCentral

113.

Varshavsky AJGtc. The N-end rule pathway of protein degradation. Genes Cells. 1997;2(1):13–28. https://doi.org/10.1046/j.1365-2443.1997.1020301.x.CrossRefPubMed

114.

Ikai AJTJoB. Thermostability and aliphatic index of globular proteins. Biochemistry. 1980;88(6):1895–8. https://doi.org/10.1093/oxfordjournals.jbchem.a133168.CrossRef

115.

Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VKJSr. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep. 2017;7(1):1–13. https://doi.org/10.1038/s41598-017-09199-w.CrossRef

116.

Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, BenMohamed LJJov. Th-cytotoxic T-lymphocyte chimeric epitopes extended by N ε-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+Tc1 responses and protect against ocular infection. J Virol. 2005;79(24):15289–301. https://doi.org/10.1128/JVI.79.24.15289-15301.2005.CrossRefPubMedPubMedCentral

117.

Brooks LR, Mias GI. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention. Front Immunol. 2018;9:1366. https://doi.org/10.3389/fimmu.2018.01366.CrossRefPubMedPubMedCentral

118.

Bibi S, Ullah I, Zhu B, Adnan M, Liaqat R, Kong W-B, et al. In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology. Sci Rep. 2021;11(1):1–16. https://doi.org/10.1038/s41598-020-80899-6.CrossRef

119.

Omoniyi AA, Adebisi SS, Musa SA, Nzalak JO, Bauchi ZM, Bako KW, et al. In silico design and analyses of a multi-epitope vaccine against crimean-congo hemorrhagic fever virus through reverse vaccinology and immunoinformatics approaches. Sci Rep. 2022;12(1):1–17. https://doi.org/10.1038/s41598-022-12651-1.CrossRef

120.

Pandey RK, Bhatt TK, Prajapati VKJSr. Novel immunoinformatics approaches to design multi-epitope subunit vaccine for malaria by investigating anopheles salivary protein. Sci Rep. 2018;8(1):1–11. https://doi.org/10.1038/s41598-018-19456-1.CrossRef

Title: In silico designing of a novel epitope-based candidate vaccine against Streptococcus pneumoniae with introduction of a new domain of PepO as adjuvant
Authors: Zohreh Bahadori
Mona Shafaghi
Hamid Madanchi
Mohammad Mehdi Ranjbar
Ali Akbar Shabani
Seyed Fazlollah Mousavi
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Pneumococcus
Published in: Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-022-03590-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Global research trends and foci of artificial intelligence-based tumor pathology: a scientometric study

Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway

Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients

Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage